JointMedica

JointMedica is a specialist developer of innovative hip resurfacing implants, notably the Polymotion Hip Resurfacing (PHR®) system, designed for active patients seeking bone preservation and a more natural biomechanical restoration than traditional total hip replacement. Early clinical experience demonstrates a greater than 95% survivorship rate in 174 patients (2015–2022)[1]. The IDE study for PHR® in the U.S. has surpassed 60% patient enrolment as of late 2025, with regulatory approval expected within 2–3 years[1][2]. Patient outcomes include improved hip function and activity levels, with current data supporting safety and efficacy, especially in young, active populations[2].